Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pallavi Sachdev

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 28, 2024
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's diseaseViswanath Devanarayan, Thomas Doherty, Arnaud Charil, et al.
British Journal of Cancer|June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer, Divyanshu Dua, Nicola Cresti, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 9, 2010
Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cellsBoris Tchernychev, Yong Ren, Pallavi Sachdev, et al.
Alzheimer'S Research & Therapy|April 23, 2026
Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ<sup>+</sup> and Aβ<sup>-</sup> dementia with Lewy bodies patientsMarlies Oosthoek, Sjors G J G In 't Veld, Lisa Vermunt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 22, 2024
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's diseaseViswanath Devanarayan, Arnaud Charil, Kanta Horie, et al.
Journal of the American Chemical Society|September 13, 2011
Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4Jay M Janz, Yong Ren, Richard Looby, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Brain : a Journal of Neurology|January 21, 2026
Plasma pTau 217:β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathologyNatalya Benina, Luna Buitrago, Francesca I De Simone, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 28, 2024
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's diseaseViswanath Devanarayan, Thomas Doherty, Arnaud Charil, et al.
British Journal of Cancer|June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer, Divyanshu Dua, Nicola Cresti, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 9, 2010
Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cellsBoris Tchernychev, Yong Ren, Pallavi Sachdev, et al.
Alzheimer'S Research & Therapy|April 23, 2026
Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ<sup>+</sup> and Aβ<sup>-</sup> dementia with Lewy bodies patientsMarlies Oosthoek, Sjors G J G In 't Veld, Lisa Vermunt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 22, 2024
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's diseaseViswanath Devanarayan, Arnaud Charil, Kanta Horie, et al.
Journal of the American Chemical Society|September 13, 2011
Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4Jay M Janz, Yong Ren, Richard Looby, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Brain : a Journal of Neurology|January 21, 2026
Plasma pTau 217:β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathologyNatalya Benina, Luna Buitrago, Francesca I De Simone, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Pageof 4